Alzheimer disease begins decades before any symptoms, such as memory loss, start to show. Consequently, early diagnosis increases the chances of slowing the disease down with drugs. A new study on an inherited form of the disease shows that a protein called GFAP is a possible biomarker for very early stages of the disease. The study could one day lead to an earlier detection of this serious and common disease.